Macrogenics
MGNX
Macrogenics (MGNX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.57
- EPS estimate
- −$0.42
- EPS surprise
- −34.66%
- Revenue surprise
- −29.77%
- Revenue
- $22.2M
- Revenue estimate
- $31.7M
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$0.42 | −$0.57 | −34.66% | $22.2M | SEC |
| Q1 2025 | May 13, 2025 | −$0.73 | −$0.65 | +10.43% | $13.2M | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.28 | −$0.24 | +13.92% | $19.4M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.21 | $0.90 | +325.53% | $110.7M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.66 | −$0.89 | −34.66% | $10.8M | SEC |
| Q1 2024 | May 9, 2024 | −$0.64 | −$0.84 | −30.72% | $9.1M | SEC |
| Q4 2023 | Mar 7, 2024 | −$0.15 | −$0.74 | −382.08% | $10.7M | SEC |
| Q3 2023 | Nov 6, 2023 | −$0.10 | $0.28 | +393.81% | $10.4M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.52 | $0.92 | +276.58% | $13.1M | SEC |
| Q1 2023 | May 9, 2023 | $0.45 | −$0.61 | −234.84% | $24.5M | SEC |
| Q4 2022 | Mar 15, 2023 | $0.10 | $0.21 | +104.70% | $73.1M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.38 | −$0.40 | −4.28% | $41.7M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.98 | −$0.67 | +31.56% | $26.0M | SEC |
| Q1 2022 | May 3, 2022 | −$0.85 | −$1.08 | −27.22% | $11.1M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.81 | −$0.95 | −16.59% | $14.1M | SEC |
| Q3 2021 | Nov 2, 2021 | −$0.71 | −$0.86 | −21.04% | $15.7M | SEC |
| Q2 2021 | Jul 29, 2021 | −$0.46 | −$0.66 | −44.90% | $30.8M | SEC |
| Q1 2021 | Apr 29, 2021 | −$0.64 | −$0.90 | −41.00% | $16.9M | SEC |
| Q4 2020 | Feb 25, 2021 | −$0.73 | $0.04 | +105.49% | $52.7M | SEC |
| Q3 2020 | Nov 4, 2020 | −$0.93 | −$0.66 | +29.09% | $18.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Macrogenics (MGNX) last report earnings?
Macrogenics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did MGNX beat earnings estimates?
No. Macrogenics reported EPS of −$0.57 for Q2 2025 against a −$0.42 estimate — a 34.66% miss.
How much revenue did MGNX report last quarter?
Macrogenics reported $22.2M in revenue for Q2 2025, against a consensus estimate of $31.7M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.